The future is here: a non-invasive method for the early diagnosis of cancer

Technological progress has brought about many changes in the field of medicine. Methods that in the past were considered science fiction, are now used as an alternative for diagnosing diseases without invading the patient’s body. For example, the use of robotic surgery was previously considered impossible, but today it is an accepted practice in hospitals. Similarly, the development of artificial organs and prostheses has revolutionized the way we treat patients. These are just two examples of how science fiction has become reality in the field of medicine.

As for cancer, in the past biopsy was the most common method for diagnosing prostate cancer, however, traditional biopsies that require taking a sample from the organ where the tumor is located are an invasive procedure. Moreover, the organ is not always accessible for sampling and it is often difficult to sample the infected area. In addition, it is an invasive operation that is sometimes done under anesthesia, causing discomfort to patients with a risk of complications such as infection and bleeding.

Liquid biopsy is a non-invasive diagnostic technique that involves the analysis of various biomarkers present in body fluids such as blood, urine and saliva. This technique, which is performed from a simple blood sample, is easy and fast for the patient, and has gained significant attention in recent years due to its potential to detect cancer at an early stage, monitor the progress of the disease and predict the response to treatment. This technique is less invasive than traditional biopsy methods, which require the removal of tissue samples from the body.

The liquid biopsy is already revolutionizing the diagnosis and treatment of cancer, and ongoing studies are examining its use in other diseases as well. While blood tests may not completely replace biopsies in all cases, they offer a promising alternative that can save patients time, discomfort, and risk.

In recent months, a non-invasive method for diagnosing prostate cancer entered Israel as part of the advanced category of liquid biopsy. This is a new blood test that makes it possible to detect aggressive prostate cancer with an impressive accuracy rate of about 90%. The revolutionary aspect of the test called IsoPSA lies in the decoding technology, which identifies changes in the structure of the protein extracted from the blood sample that result solely from the development of a cancerous tumor. As a result, doctors can more reliably determine how likely a patient is to have significant prostate cancer. The test is a new diagnostic tool developed by researchers at the Cleveland Clinic in the United States.

One of the main advantages of the test is its ability to reduce the number of unnecessary biopsies. Because by using it, doctors can identify which patients have a high risk of prostate cancer and only refer them to a biopsy, and which patients can completely avoid the need for this invasive operation. The test was recently approved by the Ministry of Health and has already revolutionized the field of prostate cancer diagnosis in Israel.

Illustration AI. Liquid biopsy laboratory. Created by Nava Inbar for Medical Link

Prof. Ofer Nativ, a senior urologist at the Elisha Hospital and former director of the urology department at the Bnei Zion Medical Center, who serves as a scientific consultant for tests in Israel, explains that: “This is a diagnostic revolution, which allows men to undergo an easy and quick procedure of a simple blood test and for us as doctors to more accurately diagnose the prostate cancer. It is essential that doctors offer their patients the most advanced test developed by the scientific community, which has proven its reliability in clinical studies. Because the goal is to prevent unnecessary biopsies in cases where patients do not have a clinically significant tumor. Thanks to the decoding of IsoPSA, we refer only those with a real risk of aggressive prostate cancer to an invasive biopsy.”

A recent study conducted at the Cleveland Clinic in the United States, one of the leading cancer treatment centers in the world, showed that men who underwent an early diagnosis using the IsoPSA test and received normal results in both the blood test and the biopsy have only a 1% risk of developing aggressive prostate cancer within 18 months (the follow-up period in the study). . In this context, Prof. Ofer Nativ emphasized that: “These are very important results because a biopsy does not detect about 15-20% of aggressive prostate cancer cases, so if an IsoPSA test is performed and it is normal, the risk of developing a clinically significant tumor drops to only about 1% . Moreover, the risk of missing a tumor also decreases, not only during the test but also in the next 18 months.”

It should be noted that prostate cancer is the most common malignancy among men in Israel and in the world, according to the data of the Cancer Society and the Ministry of Health, in the last year about 2,800 new patients were discovered and about 500 men died of the disease.

Illustration AI. Liquid biopsy laboratory. Created by Nava Inbar for Medical Link

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Enable Notifications OK No thanks